Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

As for GBS itself, this neurological ailment can be severe, attacking nerves and warranting hospitalisation for weeks or ...

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...

GSK’s vaccine Arexvy and Pfizer’s vaccine Abrysvo were ... or what health officials would consider “normal” side effects of a vaccine, like soreness, fatigue, redness at the shot site ...

The FDA has required the manufacturers of the RSV Vaccines Abrysvo and Arexvy to add a new warning to their labels about the ...

In older adults, side effects following Arexvy appear to be similar to other ... it is anticipated the RSV vaccine would be a one-off dose, at least at this stage. Younger babies don't tend ...

“When we compared the antibody responses between those study participants who received Arexvy with those who got Abrysvo, we found that the group receiving the adjuvanted vaccine tended to have ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...

Investing.com -- The US Food and Drug Administration (FDA) on Tuesday directed that vaccines for a common respiratory virus ...

The respiratory syncytial virus (RSV) vaccine may not protect older adults who are immunocompromised as much as their healthier peers, according to new research.

mResvia’s prescribing information indicates that the vaccine ... side effect seen with both GSK and Pfizer’s products. There’s still one more step before Moderna’s vaccine can take on ...